Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „monotherapy“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Of the 1 550 patients treated with BRUKINSA monotherapy, 61.3% were 65 years of age or older. The incidence of
Eintrag öffnenBrukinsa · 4.8 · Of the 1 550 patients treated with BRUKINSA monotherapy, 61.3% were 65 years of age or older. The incidence of
Eintrag öffnenBrukinsa · 4.8 · Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell ma
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib monotherapy is based on pooled data from 1 550 patients with B- cell malign
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib monotherapy is based on pooled data from 1 550 patients with B- cell malign
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib monotherapy
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib monotherapy
Eintrag öffnenCabometyx · 4.8 · Cabozantinib as monotherapy Summary of safety profile The most common serious adverse drug reactions in the RC
Eintrag öffnenCalquence · 4.8 · Calquence monotherapy
Eintrag öffnenCalquence · 4.8 · Calquence monotherapy
Eintrag öffnenCalquence · 4.8 · Of the 1 478 patients in clinical studies of Calquence monotherapy, 42% were greater than 65 years and less th
Eintrag öffnenCalquence · 4.8 · Of the 1 478 patients in clinical studies of Calquence monotherapy, 42% were greater than 65 years and less th
Eintrag öffnenCalquence · 4.8 · Of the 1 478 patients treated with Calquence monotherapy, discontinuation due to adverse reactions were report
Eintrag öffnenCalquence · 4.8 · Of the 1 478 patients treated with Calquence monotherapy, discontinuation due to adverse reactions were report
Eintrag öffnenCalquence · 4.8 · Of the 1 478 patients treated with Calquence monotherapy, the most common (≥ 20%) adverse drug reactions (ADRs
Eintrag öffnen